Entrada Therapeutics Inc (TRDA)

Over the past six months, Entrada Therapeutics' stock price has decreased by 22.74%. The stock price has decreased by 63.87% over the last 12 months, and year-to-date, it has seen a return of -68.65%. As of October 13, 2025, the share price was $5.81. Key events impacting the stock price include the Q2 2025 earnings report, which showed that Entrada Therapeutics reported a Q2 EPS of ($1.04), missing analysts' estimates of ($0.86) by ($0.18), and the company's revenue for the quarter was $1.98 million, significantly below analysts' expectations of $8.17 million. Analyst rating changes include Wall Street Zen cutting Entrada Therapeutics from a "hold" to a "sell" rating on August 9th, 2025, Zacks Research upgrading the stock to a "hold" rating on August 8th, 2025, and Weiss Ratings restating a "sell (D-)" rating on October 25, 2025, and October 8, 2025. Entrada Therapeutics received EU authorization to proceed with its ELEVATE-45-201 clinical study for Duchenne Muscular Dystrophy, set to begin in Q3 2025. A director at TRDA sold 6,422 shares. The company announced participation in the Jefferies Global Healthcare Conference in London (November 18, 2025) and the 8th Annual Evercore Healthcare Conference in Miami, FL (December 3, 2025).

As a clinical-stage biopharmaceutical company, Entrada Therapeutics, Inc. does not currently have any products approved for commercial sale, so there is no demand seasonality for its products or services. The company's revenue is primarily generated through strategic collaborations and licensing agreements.

Entrada Therapeutics, Inc. (TRDA), founded in 2016 and based in Boston, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing therapies for underserved diseases. They utilize their proprietary Endosomal Escape Vehicle (EEV™) technology to deliver therapeutic payloads directly to cells. The company's mission is to create new medicines for debilitating diseases with limited treatment options, focusing on rare genetic diseases, oncology, and immunology. Key product candidates include ENTR-001 for Wolfram syndrome, EN401 for Duchenne muscular dystrophy (DMD), and EN301 for lysosomal storage diseases. They also partner to develop VX-670 for myotonic dystrophy type 1.

Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. While they have received EU authorization for a clinical study for Duchenne Muscular Dystrophy, indicating international reach, there is no specific geographic segmentation data available for its revenue, as it primarily generates revenue through strategic collaborations and licensing agreements.

Entrada Therapeutics' brand reputation over the past year is mixed, influenced by both positive developments and financial performance challenges. The company has a consensus rating of "Moderate Buy" from analysts, with an average target price of $25.67. However, individual analyst ratings vary, including "Strong Buy," "Buy," "Hold," and "Sell" recommendations. The Q2 2025 earnings report, which showed a significant miss on both EPS and revenue estimates, likely negatively impacted its reputation. The EU authorization to proceed with a clinical study for Duchenne Muscular Dystrophy is a positive development. The announcement of recipients for the Third Annual DREAMS Grant Program in September 2025 could contribute positively to its reputation. Varied and sometimes negative analyst ratings suggest ongoing scrutiny of the company's prospects and financial health.

Entrada Therapeutics, Inc. has a diverse ownership structure. Approximately 82.52% of the total shares outstanding are held by institutional investors. Major institutional owners include Baker Bros. Advisors Lp, MPM Asset Management Llc, and 5AM Venture Management, LLC. Felix Baker owns the most shares among individual investors. Insiders own approximately 48.23% of the company's stock, while public companies and individual investors own about 8.80%.